title: Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preference.
authors.affiliation: Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Tullia
authors.initials: T
authors.lastname: Rushton
authors.affiliation: Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Aban
authors.affiliation: Radiology, Children's of Alabama, Birmingham, AL, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Young
authors.affiliation: Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Howard
authors.affiliation: Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Lee
authors.initials: L
authors.lastname: Hilliard
authors.affiliation: Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Lebensburger
mesh_terms: D002544:Cerebral Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D008297:Male; D057240:Patient Preference
chemical_list: D006918:Hydroxyurea
keywords: hydroxycarbamide; patient preference; sickle cell disease; silent infarct; stroke